ArticleOncology letters2026
Pregnancy with vitrified oocytes after fertility sparing surgery in a patient with fallopian tube cancer and a BRCA2 mutation: A case report and literature review.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade carcinomas affecting the ovary or peritoneum may originate from the epithelium of the fallopian tubes. Whilst gynecological cancers are more frequent in post-menopausal patients, 12.1% of ovarian malignancies are diagnosed in patients of childbearing age, aged <45 years. There is not enough data to provide an accurate estimate on the incidence of relapse, the chance of pregnancy and outcomes of assisted reproduction and fertility-sparing surgery techniques in young patients with ovarian cancer. Moreover, there is currently a lack of data regarding fertility preservation techniques for patients with cancer of the fallopian tubes. To the best of our knowledge, the present report describes the first live newborn birth using vitrified oocytes retrieved before fertility-sparing surgery for primary fallopian tube cancer (stage IC1) in a patient with a BRCA2 mutation. Furthermore, a narrative review of literature from 2000-2024 from several online databases was performed to identify articles involving patients with fallopian tube cancer and BRCA mutations, who underwent fertility preservation with vitrified oocytes and fertility-sparing surgery. A total of 44 manuscripts were retrieved, with only two articles reporting data on pregnancy with vitrified oocytes after fertility-sparing surgery, and 3 cases included. Whilst more research is required for assisted reproductive technology and ovarian cancer, and for the elucidation of the role of BRCA mutations on fertility, the present report aims to provide impetus to further research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.